版本:
中国

Biogen Inc (BIIB.O)

BIIB.O ( 纳斯达克 )

335.16USD
20 Feb 2019
涨跌 (%)

$2.16 (+0.65%)
收盘
$333.00
开盘
$332.37
当日最高
$335.30
当日最低
$331.57
成交量
859,919
平均成交量
1,360,694
52 周最高
$388.67
52 周最低
$249.17

Chart for

概况

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious... (更多)

概况

Beta: 1.10
市值(百万): $65,504.02
已发行股本(百万): 196.71
股息: --
股息收益率 (%): --

财务指标

  BIIB.O Industry Sector
P/E (TTM): 15.33 32.66 36.18
EPS (TTM): 21.72 -- --
ROI: 21.27 13.07 12.67
ROE: 34.73 14.08 13.70

UPDATE 2-Biogen beats estimates on multiple sclerosis drugs sales

Jan 29 Biogen Inc beat analysts' estimates for fourth-quarter profit and revenue on Tuesday, buoyed by higher sales of its top-selling multiple sclerosis drugs, and forecast full-year profit ahead of Wall Street expectations. 全文
01/30 00:56

CORRECTED-UPDATE 1-Biogen beats estimates on Spinraza, Tecfidera strength

Jan 29 Biogen Inc beat analysts' estimates for fourth-quarter profit and revenue on Tuesday, driven by demand for its muscle disease treatment Spinraza and top-selling multiple sclerosis drug Tecfidera. 全文
01/29 20:24

Drugmaker Biogen's fourth-quarter revenue rises 6.6 pct

Jan 29 Biogen Inc reported a 6.6 percent rise in fourth-quarter revenue on Tuesday, driven by higher sales of its blockbuster muscle disease treatment Spinraza. 全文
01/29 19:39

UPDATE 3-AbbVie expects steeper decline in Humira's overseas sales; shares fall

Jan 25 AbbVie Inc said on Friday it expects a steeper decline in overseas sales of its top-selling drug, Humira, due to intense competition from cheaper versions in Europe, driving its shares down nearly 7 percent. 全文
01/26 00:05

AbbVie profit misses as Humira faces biosimilar challenge in Europe

Jan 25 AbbVie Inc on Friday posted a fourth-quarter profit that missed Wall Street estimates, as the drugmaker's top-selling drug, Humira, faces competition from cheaper rival versions in Europe. 全文
01/25 20:45

CORRECTED-Samsung Bioepis biosimilar to Roche's Herceptin wins FDA nod

Jan 18 The U.S. Food and Drug Administration said on Friday it had approved a biosimilar to Roche Holding AG's blockbuster breast cancer treatment, Herceptin. 全文
01/19 05:25

Best U.S. fund managers of '18 buying healthcare, pot stocks as market wobbles

NEW YORK, Jan 15 The top-performing U.S. growth fund managers of the last year are taking the recent slide in the U.S. stock market to add to their bets in companies they expect will continue to expand regardless of the direction of the overall economy. 全文
01/16 03:43

CORRECTED-BRIEF-Banner Gets FDA Tentative Approval For Multiple Sclerosis Treatment Bafiertam

* BANNER RECEIVES FDA TENTATIVE APPROVAL FOR BAFIERTAM FOR THE TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS 全文
01/02 22:05

Biotech swoon adds to Nasdaq's pain as bear market looms ever closer

NEW YORK, Dec 21 As the Nasdaq Composite continues to stumble its way toward a bear market, biotech shares are worsening the collapse of the tech-heavy index. 全文
12/22 03:42

Swiss stocks - Factors to watch on Dec. 21

ZURICH/BERLIN, Dec 21 The Swiss blue-chip SMI, which is down 10.3 percent on the year, was seen opening 0.1 percent lower at 8,404 points on Friday, according to premarket indications by bank Julius Baer. 全文
12/21 15:34

竞争者

  现值 涨跌额
Johnson & Johnson (JNJ.N) $136.35 +0.66
Pfizer Inc. (PFE.N) $42.20 -0.40
Novartis AG (NOVN.S) CHF90.68 +0.64
Merck & Co., Inc. (MRK.N) $79.43 +0.19
Roche Holding Ltd. (ROG.S) CHF276.70 +2.10
Roche Holding Ltd. (RO.S) CHF273.60 +2.20
Bayer AG (BAYGn.DE) €68.36 +0.56
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €74.20 -0.47
GlaxoSmithKline plc (GSK.L) 1,574.00 +3.40

收益 vs. 预测